Drug intelligence / Profile preview

Shinbaro + non-steroidal anti-inflammatory drugs

Development stage
Unknown
Lead developer
GC Biopharma
Modality
Small Molecules
Administration
Oral, Intramuscular
01

Overview

**Shinbaro + non-steroidal anti-inflammatory drugs (NSAIDs)** refers to the combination therapy of Shinbaro, a standardized herbal formulation approved in South Korea for osteoarthritis, with NSAIDs such as celecoxib. Shinbaro is a purified extract of six oriental herbs: Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, and Eucommiae Cortex. This combination aims to provide enhanced anti-inflammatory and pain-relieving effects while potentially reducing the required dosage and side effects of NSAIDs. Scientific studies, including controlled animal models, show that co-administration with celecoxib (a selective COX-2 inhibitor) results in a synergistic reduction of pain and swelling, mediated through inhibition of monocyte-to-macrophage conversion, suppressed inflammatory cytokine production, and reduced spinal microglial activation. The combination is being investigated as an alternative or adjunct strategy for inflammatory pain management, especially for conditions such as osteoarthritis and rheumatoid arthritis[2][4].

Other names
Shinbaro + NSAIDsShinbaro + celecoxib
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TNFA (Tumor necrosis factor alpha (soluble))NOS2 (Nitric Oxide Synthase 2)IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on Shinbaro + non-steroidal anti-inflammatory drugs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shinbaro + non-steroidal anti-inflammatory drugs.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call